Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling of Ampicillin and Gentamicin in Peripartum Patients

• Status: Completed
• Trial end date: 2017-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study proposes to compare the metabolism of Ampicillin and Gentamicin by pregnant women to that of non-pregnant women; the placental transfer over time; and the subsequent metabolism of the transferred drug(s) in the neonate.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Collaborator: David Drover, MD
• Treatments: Ampicillin; Gentamicins

Criteria

Inclusion Criteria:

• Generally healthy, pregnant woman (28-42 weeks)

• Generally healthy, non-pregnant female

• Scheduled to receive Ampicillin and/or Gentamicin IV

• Ages 18-55 years old

• Relatively normal Comprehensive Metabolic Panel (if available), as evidenced by recent blood work

• Able and willing to sign consent

Exclusion Criteria:

• Women with known renal or hepatic impairment; preeclampsia; Diabetes, including Gestational; any medical condition that, in the opinion of the Investigator or research team member, could potentially interfere with the study objectives

• Women who are participating in another study

• Pregnant with multiples

• BMI > 40